Fluroxene (INN, USAN; brand name Fluoromar), or 2,2,2-trifluoroethyl vinyl ether, is a volatile, inhalational anesthetic.[1][2] It was synthesized in 1951, and was introduced for clinical use in 1954, but was voluntarily withdrawn from the market in 1974 due to its potential flammability and accumulating evidence that it could cause organtoxicity.[2][1][3] In any case, prior to being discontinued, it had largely been superseded by halothane.[4] Fluroxene is metabolized to 2,2,2-trifluoroethanol, a compound responsible for some of the toxicity seen with fluroxene use.[5][6]
^ abStoelting RK, Hillier SC (11 January 2012). "Inhaled Anesthetics". Pharmacology and Physiology in Anesthetic Practice. Lippincott Williams & Wilkins. pp. 142–. ISBN978-1-4511-6583-8.
^ abJakob AK, Kopp SL, Bacon DR, Smith HM (1 January 2011). "Chapter 1: the History of Anesthesia". In Barash PG, Cullen BF, Stoelting RK, Cahalan M, Stock MC (eds.). Clinical Anesthesia. Lippincott Williams & Wilkins. pp. 113–. ISBN978-1-4511-2297-8.
^Kaminsky LS, Fraser JM (1988). "Multiple aspects of the toxicity of fluroxene and its metabolite 2,2,2-trifluoroethanol". Critical Reviews in Toxicology. 19 (2): 87–112. doi:10.3109/10408448809014901. PMID2906849.
